Scholar Rock gets FDA fast track for apitegromab FSHD Phase 2 FORGE
Scholar Rock received FDA Fast Track Designation for its apitegromab FSHD program as participant dosing started in Phase 2 of the FORGE trial.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.